Core Viewpoint - The article highlights the transformative journey of the Chinese pharmaceutical industry from "catching up" to "leading," exemplified by the career of Qian Jiang, who has witnessed and contributed to significant changes over three decades [4][6]. Group 1: Career Development and Industry Changes - Qian Jiang's career reflects the evolution of the Chinese pharmaceutical sector, transitioning from a time when patients waited 8-10 years for innovative drugs to a present where rapid advancements are being made [1][4]. - The pharmaceutical industry in China is experiencing a shift towards innovation, with Qian emphasizing the importance of embracing change and technology, particularly artificial intelligence, to enhance efficiency and speed in drug development [8][9]. - The average time for scientific innovation to reach clinical application remains at 17 years, highlighting a significant gap that the industry aims to close [8]. Group 2: Personal Philosophy and Leadership - Qian Jiang views himself as a "fortunate child of the era," attributing his career advancements to the broader changes in the pharmaceutical landscape [3][11]. - His leadership philosophy centers on the idea that the role of pharmaceutical executives has evolved from mere management to becoming pioneers who connect global and local innovation ecosystems [14][15]. - The commitment to patient-centered care is a core value for Qian, emphasizing that the ultimate goal of pharmaceutical work is to improve patients' lives [19][20]. Group 3: Strategic Vision for BMS - BMS China aims to leverage its long-standing presence and adapt to the changing pharmaceutical ecosystem by fostering innovation and collaboration [15][16]. - The company’s strategy includes a commitment to delivering innovative drugs more rapidly to patients, reflecting a long-term vision for growth and value creation [16][24]. - Qian Jiang's experience in both multinational corporations and local biotech firms positions him uniquely to drive BMS's strategic initiatives in China [13][14].

Core Insights - Hypertrophic Cardiomyopathy (HCM) is the most common single-gene hereditary heart disease, characterized by asymmetric hypertrophy of the myocardium, with obstructive HCM having a lower survival rate [2][23] - Mavacamten, a first-in-class myosin inhibitor, targets the core pathophysiological mechanisms of HCM, representing a significant advancement in treatment options [2][17] Group 1: Disease Overview - HCM affects approximately 0.2% to 0.5% of the global population, with an estimated 2 million patients in China [2][23] - Patients with obstructive HCM experience symptoms such as dyspnea, fatigue, chest pain, and syncope, which severely limit their daily activities and mental well-being [2][23] Group 2: Mavacamten Development - Mavacamten is the first drug to provide targeted intervention at the pathophysiological level, differing from traditional symptomatic treatments like beta-blockers and calcium channel blockers [4][25] - The EXPLORER-HCM trial demonstrated that Mavacamten significantly improves exercise capacity, left ventricular outflow tract (LVOT) obstruction, and overall health status compared to placebo [6][27] Group 3: Clinical Trials in China - The EXPLORER-CN trial, led by Professor Zhang Shuyang, is the first randomized, double-blind, placebo-controlled study specifically for symptomatic obstructive HCM patients in China [12][28] - Results from EXPLORER-CN showed significant improvements in LVOT peak pressure gradient and other clinical parameters after 30 weeks of treatment with Mavacamten [13][32] Group 4: Safety and Efficacy - Mavacamten treatment resulted in consistent benefits across various subgroups, including gender, age, and baseline NYHA classification, with no new safety signals identified [13][28] - The drug demonstrated positive effects on cardiac structure and diastolic function, as evidenced by reductions in left ventricular mass index and wall thickness [14][34] Group 5: Global Contribution and Future Prospects - Chinese clinical data and research have enriched the global evidence base for Mavacamten, highlighting the role of Chinese researchers in advancing scientific understanding of HCM [16][37] - Mavacamten was approved for use in China in April 2024, marking a significant milestone in providing a root-cause treatment option for obstructive HCM patients [18][17]

Core Insights - Bristol-Myers Squibb (BMS) is shifting its strategic focus in China from merely expanding market presence to co-creating an innovative ecosystem, emphasizing mutual empowerment and innovation as key objectives [1][2] Group 1: Strategic Focus - BMS's "China 2030 Strategy" was introduced in 2020, aiming to maintain steady performance, integrate and lead innovation ecosystems, and enhance talent development [2] - The three strategic focuses—performance, innovation, and talent—are interrelated, forming a closed loop that ensures China remains a core market globally [3] Group 2: Performance as a Foundation - Performance encompasses not only commercial success but also the synchronization of Phase III clinical trials and new drug registrations, aiming to enhance patient accessibility and impact from diagnosis to treatment [4] - Since the implementation of the "China 2030 Strategy," BMS has accelerated the introduction of innovative drugs, focusing on areas with unmet medical needs, including several global firsts in drug categories [4] - BMS has successfully integrated five innovative products into the national medical insurance directory within a year of their market launch, demonstrating a new speed in market access [4] Group 3: Innovation as an Engine - BMS aims to transition from being an innovator's importer to a leader in China's innovation ecosystem, emphasizing the importance of mutual empowerment with local partners [6] - The company seeks to identify Chinese innovations that can benefit global patients, focusing on strategic alignment with core disease areas and long-term value creation [6] Group 4: Talent as a Bridge - BMS is building a talent pool that understands both the Chinese market and global dynamics, essential for executing its "China 2030 Strategy" [7][8] - The company emphasizes the importance of diverse experiences in its talent acquisition and promotes cross-regional and cross-functional opportunities for internal development [8][9] Group 5: Long-term Vision - BMS's commitment to the Chinese market remains steadfast, evolving from a focus on market potential to recognizing the value of China's innovative ecosystem [9] - The company believes that understanding the vibrancy and resilience of the Chinese market will enhance its development prospects, aiming for dual innovation and empowerment as pathways to success [9]

Core Viewpoint - Bristol-Myers Squibb (BMS) has shifted its perspective on the Chinese market from merely a sales opportunity to a collaborative innovation ecosystem, emphasizing mutual empowerment and innovation as key goals [2][3]. Group 1: Strategic Focus - The year 2025 is identified as a pivotal year for BMS in China, marking a transition from market expansion to ecosystem co-creation [2]. - BMS's "China 2030 Strategy," initiated in 2020, aims to maintain robust performance, integrate and lead innovation ecosystems, and enhance talent development [3]. - The three strategic focuses of performance, innovation, and talent are interrelated, forming a cohesive framework for BMS's operations in China [4]. Group 2: Performance as a Foundation - Performance encompasses not only commercial success but also the synchronization of Phase III clinical trials and new drug registrations with global standards [6]. - BMS has accelerated the introduction of innovative drugs in China, focusing on areas with unmet medical needs, including several first-in-class and best-in-class therapies [6]. - The company has successfully integrated five innovative products into the national medical insurance directory within a year of their launch, showcasing a new speed in market access [6][8]. Group 3: Innovation as an Engine - BMS aims to transition from being an innovator's "importer" to a leader within China's innovation ecosystem, emphasizing the importance of collaboration with local partners [11]. - The selection of partnerships is guided by strategic alignment with BMS's core disease areas and the potential for long-term value creation [12]. Group 4: Talent as a Bridge - BMS is building a talent pool that understands both the Chinese market and global dynamics, essential for executing its "China 2030 Strategy" [14]. - The company encourages cross-regional and cross-functional experiences to enhance employees' global perspectives while being rooted in local market needs [14]. Group 5: Long-term Vision - BMS remains committed to a patient-centered approach and innovation as its core competitive advantage, with a strong belief in the resilience and potential of the Chinese market [15].